drugset / Trial / NCT06866236

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

NCT06866236 ↗

Phase 2/3 Not yet recruiting 3000 enrolled Ebima Clifford Okundaye
RandomizedParallel-groupSingle-blindTreatment

Summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Timeline

Start
2025-10
Primary completion
2026-10
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator QRX-3 Unknown — Oral